IL4 and hepatocellular carcinoma: found that HCC cells can promote the secretion of IL4 by sorafenib and trigger the formation of MET, which promotes SR by inhibiting ferroptosis in HCC cells, suggesting that targeting the IL4/PADI4/MET axis in HCC can reduce or prevent SR (76).